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Objective: The influence of biological sex on human immunodeficiency virus (HIV) antiretro-
viral treatment outcome is not well described in HIV–hepatitis C (HCV) coinfection.
Methods: We assessed patients’ clinical outcomes of HIV–HCV coinfected patients initiating 
antiretroviral therapy attending the Ottawa Hospital Immunodeficiency Clinic from January 
1996 to June 2008.
Results: We assessed 144 males and 39 females. Although similar in most baseline charac-
teristics, the CD4 count was higher in females (375 vs 290 cells/µL). Fewer females initiated 
ritonavir-boosted regimens. The median duration on therapy before interruption or change was 
longer in males (10 versus 4 months) (odds ratio [OR] 1.40 95% confidence interval: 0.95–2.04; 
P = 0.09). HIV RNA suppression was frequent (74%) and mean CD4 count achieved robust (over 
400 cells/µL) at 6 months, irrespective of sex. The primary reasons for therapy interruption in 
females and males included: gastrointestinal intolerance (25% vs 19%; P = 0.42); poor adherence 
(22% vs 15%; P = 0.31); neuropsychiatric symptoms (19% vs 5%; P = 0.003); and lost to 
  follow-up (3% vs 13%; P = 0.08). Seven males (5%) and no females discontinued therapy for 
liver-specific complications. Death rate was higher in females (23% vs 7%; P = 0.003).
Conclusion: There are subtle differences in the characteristics of female and male HIV–HCV 
coinfected patients that influence HIV treatment decisions. The reasons for treatment interruption 
and change differ by biological sex. This knowledge should be considered when starting HIV 
therapy and in efforts to improve treatment outcomes.
Keywords: AIDS, HIV , HCV , coinfection, HAART, viral load, women, gender differences, 
outcome, CD4 cell counts
Introduction
The natural history and clinical outcomes in human immunodeficiency virus (HIV) 
may differ by biological sex.1 When highly-active antiretroviral therapy (HAART) 
first became available, females were less likely to be on therapy and were observed to 
have diminished therapeutic outcomes.2–4 Although more recent data suggest that these 
gaps have diminished in magnitude, concerns related to decreased access and quality 
of care for females persist.2,4 Although data are conflicting, several studies suggest 
that women have lower plasma HIV RNA levels than men.1,5 Since this measure influ-
ences the timing of HAART initiate, it is plausible that women may start treatment 
later than men, which may contribute to poorer outcomes.5,6 Women may experience 
more lactic acidosis, drug toxicity and hypersensitivity reactions on antiretroviral 
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therapy which may contribute to decreased adherence and 
treatment interruption.1,7 Some studies indicate that women 
have higher rates of clinical progression to acquired immu-
nodeficiency syndrome (AIDS) and death while others 
have suggested the opposite.1,2,8 Differential access to care 
for women between studies may be an important factor 
explaining these discrepancies.1,2,8 Many women with HIV 
report high rates of poverty, are often depended on for care 
of children or family members, and may show a reluctance to 
take medication in public due to denial or fear of disclosure 
which may lead to compromised self-care, access to care, 
and response to treatment.4,9 Depression disproportionally 
affects women and may contribute to worse outcomes, as 
depressive symptoms in women are associated with hastened 
HIV progression.10
Hepatitis C virus (HCV) coinfection in HIV is common 
and contributes to increased morbidity and mortality.11 
Many of the barriers to HIV care access and treatment 
listed above are more frequent and more severe in those 
with HIV–HCV coinfection.12,13 Furthermore, HCV itself 
may negatively influence the natural history of HIV dis-
ease and therapeutic response to HAART.11 The interaction 
between HIV, HCV, and sex is an area that remains largely 
unexplored. Well-established gender differences between 
sexes in HIV–HCV coinfected women include greater 
likelihood of spontaneous clearance of acute HCV infection 
and higher symptom burden.14,15 There is no literature 
evaluating differences in HIV-related outcomes in the 
HIV–HCV coinfected population. To this end, we evaluated 
the influence of biological sex on HIV antiretroviral clinical, 
immunological, and virological outcome in a well-described 
HIV–HCV coinfected population followed in a tertiary 
care-based, specialized immunodeficiency clinic. Specific 
data on sex and HIV–HCV coinfection is important, as 
women are a rapidly growing segment of the overall HIV 
population.16,17
Methods
We assessed all HAART-treated HCV–HIV coinfected 
individuals followed at The Ottawa Hospital Immunodeficiency 
Clinic from January 1996 to June 2008. We identified 
patients in a prospective cohort of clinic attendees and 
supplemented this data by chart review. HIV RNA viral load, 
CD4 lymphocyte counts, liver enzymes and function tests, 
and HCV serology results were collected. Characteristics 
including age, history of excess alcohol, history of injection 
drug use (IDU), treatment start date, HAART composition, 
and pregnancy status were identified.
Primary outcome measures included duration of therapy 
before interruption or change, suppression of HIV RNA 
levels below detection within 6 and 12 months, mean 
CD4 counts after 6 months of HAART, and cumulative 
survival. The primary reason for treatment interruption 
was assessed. Categories included gastrointestinal side 
effects (eg, nausea, vomiting, abdominal discomfort, 
diarrhea), neuropsychiatric symptoms (eg, depression, head-
aches, difficulties with mentation, neuropathy), adherence 
difficulty, metabolic complications, liver toxicity, renal 
complications, musculoskeletal side effects, hematologic 
abnormalities, dermatologic complications, alcohol and/or 
substance abuse, pill count or dosing frequency issues, viro-
logic failure, and death. Measures of adherence were based 
on self-report and clinician suspicions of nonadherence.
We assessed baseline characteristics using parametric 
testing (t-tests and Chi-squared). Our primary outcome 
measures were analyzed using time to event analysis with a 
step-wise multivariable analysis. We consider a P-value of 
less than 0.05 as significant and all P-values are two-sided. 
Collection and analysis of this data was approved by the 
Ottawa Hospital Research Ethics Board.
Results
A total of 183 HIV–HCV coinfected HAART-treated 
patients followed from January 1996 to June 2008 were 
assessed (Table 1). Females made up 21% of the evaluated 
population. The majority were White males. A high level 
of excess alcohol use and history of IDU was noted in both 
Table 1 Baseline characteristics of HIV–HCV coinfected 
patients
Characteristic Male  
N = 144 (79%)
Female  
N = 39 (21%)
Mean age [yrs (SD)] 38.4 (7.2) 36.6 (7.6)
Mean baseline HIV RNA Level  
[copies/mL (SD)]
96,433  
(162,634)
72,922 
(113,227)
Mean baseline CD4 count  
[cells/µL (SD)]
290 (226) 375 (387)
Baseline CD4 count  
200 cells/µL
37% 42%
Mean ALT [U/L (SD)] 66 (72) 51 (42)
History of excess alcohol 37% 36%
History IDU 76% 85%
White  
Black  
Asian  
Native
86%  
8%  
1%  
5%
79%  
13%  
0%  
8%
Abbreviations: ALT, alanine aminotransferase; HCV, hepatitis C virus; HIV, human 
immunodeficiency virus; IDU, injection drug use; SD, standard deviation.Patient Preference and Adherence 2010:4 99
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sexes. A trend toward lower baseline HIV RNA levels and 
higher CD4 counts was noted in women. Four women (10%) 
initiated HAART specifically for pregnancy. There was 
no difference in baseline CD4 counts between these four 
patients and the other 35 females who started HAART. None 
of these four women or two others who became pregnancy 
while on HAART was exposed to efavirenz.
There were subtle differences in specific drugs chosen 
when assessed by sex (Table 2). A higher proportion of men 
initiated high-dose ritonavir and low-dose ritonavir-boosted 
containing therapy. More females initiated ritonavir-sparing 
(ie, nelfinavir, atazanavir) treatment. Women were less likely 
to initiate efavirenz which may reflect concerns related to 
teratogenicity risk in women of child-bearing age. Because 
the median start date for HAART was similar by sex 
(August 1999 for men; December 1998 for women), we are 
  confident that these differences in antiretroviral composition 
by sex are not a consequence of a treatment era effect bias. 
Median duration of follow-up after the initiation of therapy 
was 4.7 years for men and 5.1 years for women (P = 0.55). 
The median duration on therapy was 4 months for women 
(range: 1 to 10 months) and 10 months for men (range: 4 to 
24 months) (P = 0.01) (Figure 1). The duration on therapy 
did not differ for women started on HAART for pregnancy 
compared to women initiated on treatment for other 
  indications (data not shown). At last assessment, only 9% of 
the men and 8% of the women were on the same treatment 
regimen as the one started revealing a high turnover rate of 
antiretrovirals. Twelve percent of women and 15% of men 
stopped antiretroviral therapy without resumption, 35% of 
women and 48% of men immediately changed to a second 
line regimen without interruption, and 53% of women and 
37% of men resumed therapy but only after an interruption 
in HAART (P = 0.24).
Mean CD4 counts increased to 413 cells/µL in women 
and 400 cells/µL in men after 6 months of HAART and 
did not differ by sex. The absolute increase in CD4 cells 
from baseline was greater in males (102 versus 11 cells/µL; 
P = 0.04). The proportion achieving virological suppression 
below the lower limit of detection were similar at 6 months 
(women: 77%, men 74%; P = 0.73) and 12 months (women: 
82%, men: 81%; P = 0.87) of therapy in those remaining on 
HAART at these time points.
Both women (25%) and men (19%) (P = 0.42) cited gas-
trointestinal complications as the primary reason for HAART 
interruption (Table 3). Adherence difficulties were a common 
reason for discontinuation in women (22%) and men (15%) 
(P = 0.31). Women were more likely to stop treatment due 
to neuropsychiatric issues (P = 0.003). The use of efavirenz 
was similar in those interrupting therapy for neuropsychiatric 
complications (23%) and those not (15%; P = 0.46). Two of 
six men and one of seven women on efavirenz who stopped 
treatment for neuropsychiatric reasons did so specifically due 
to efavirenz-attributed side effects. Men were more likely 
to be lost to follow-up (P = 0.08). Liver complications were 
an infrequent cause for HAART change or interruption, 
irrespective of sex. Seven males (5%) and no females dis-
continued therapy for liver-specific complications.
Mortality analysis revealed an association between 
female sex and reduced cumulative survival (odds ratio 
[OR] = 4.46, 95% confidence intervals [CI]: 1.8–11.0; 
P = 0.001) (Figure 2). When controlled for IDU, race, and 
baseline CD4, this association remained significant. Twenty-
three percent of women and 7% of men died during the 
period of evaluation (P = 0.003). Sixty percent of deaths were 
end-stage liver disease-related and did not differ by sex.
Discussion
There is evidence that biological sex may influence HIV 
progression and treatment response.1,7 These differences are 
of ever-increasing importance given that women comprise a 
rapidly growing segment of the HIV population.16,17 Little is 
known as to how HCV coinfection influences the interaction 
between HIV and biological sex. Our findings indicate that 
HIV–HCV coinfected women are more likely to interrupt or 
change treatment before men, differ in reasons for therapy 
interruption, and may have a lower cumulative survival. 
These differences are not explained by the subtle baseline 
differences in characteristics.
Table 2 HAART composition for HIV–HCV patients starting 
treatment
Male (n = 144) Female (n = 39)
Protease inhibitor-based HAART 69% (n = 100) 77% (n = 30)
Ritonavir 70% 47%
High-dose ritonavir 39% 30%
Saquinavir 41% 40%
Indinavir 14% 20%
Nelfinavir 17% 23%
Kaletra 23% 7%
Atazanavir 0% 10%
NNRTI-based HAART 22% (n = 31) 18% (n = 7)
Efavirenz 77% 71%
Nucleoside-sparing 10% 0%
Abbreviations: HAART, highly-active antiretroviral therapy; NNRTI, non-nucleoside 
reverse transcriptase inhibitors.Patient Preference and Adherence 2010:4 100
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When  comparing  duration  on  HAART  prior  to 
  interruption or change in antiretroviral(s), differences 
between men and women were most apparent during the 
first 12 months of therapy (Figure 1). Thereafter, the rates 
were similar. The reason for differences in duration of 
therapy before interruption or change is unclear but likely 
multifactorial. Similar findings have been observed in 
HIV mono-infected populations.1 The proportion of men 
and women on the same HAART regimen after one year 
was low and did not differ by sex. Women more typically 
  interrupted HAART with a break prior to resumption of 
therapy whereas men where more likely to immediately 
switch to an alternate regimen. The reason for this is unclear. 
However, post-partum discontinuation of therapy did not 
explain this observation.
It is plausible that pregnancy may influence the timing 
of HAART initiation and therapeutic outcomes in HIV. 
Pregnancy may affect pharmacokinetics that could influence 
side effects.18–20 Pregnancy may contribute to greater drug 
intolerance in female recipients and higher rates of treatment 
discontinuation as following delivery HAART may be 
stopped depending on patient and physician preferences 
towards remaining on treatment (dependent on disease stage). 
Consistent with other studies, we did not identify a pregnancy 
effect on HIV disease progression or outcome.21,22 However, 
the number of pregnancies in our cohort was low.
In our study, virological and immunological outcomes 
did not differ by sex in those remaining on therapy. It is 
noteworthy that the baseline CD4 count at treatment initiation 
was higher in women. This difference was not explained by 
pregnant females with high CD4 counts initiating HAART 
to prevent maternal to fetal HIV transmission. It is plausible 
that more women initiated HAART earlier in the HAART 
era when higher CD4 counts triggered the introduction of 
therapy. This was not the case in our cohort as the average 
date of treatment initiation was similar by sex. We suspect 
that better compliance with scheduled clinic visits in women 
may have contributed to HAART-initiation at higher CD4 
counts. There are discrepancies between other studies with 
some reporting higher,23 lower2 or similar1,7,24,25 baseline CD4 
counts by sex. This may reflect the influence of the above 
mentioned confounders.
Consistent with other work, the primary reason for therapy 
interruption differed by sex in our analysis.26 Treatment 
adherence in our female patients was not a significant factor 
leading to treatment interruption or change. This finding is 
consistent with some, but not all analyses.24,27 It is unclear 
why so many men where lost to follow-up and to what effect 
this had on the outcomes in the study.3 Previous research by 
our group indicated that our HCV–HIV coinfected population 
faces multiple barriers to treatment including substance 
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Figure 1 Months on HAART by sex prior to interruption or treatment change.
Abbreviation: HAART, highly-active antiretroviral therapy.
Table 3 Primary reasons for therapy interruption by sex
Female Male P
Gastrointestinal complaints 25% 19% 0.42
Adherence 22% 15% 0.31
Mental health 19% 5% 0.003
Lost to follow-up 3% 13% 0.08
Substance use 5% 6% 0.79
Liver 0% 5% 0.06Patient Preference and Adherence 2010:4 101
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abuse, psychiatric illness, anxiety related to workup or 
treatment, and poor social circumstances which contribute 
to suboptimal follow-up.4
Neuropsychiatric issues were identified as an important 
reason for therapy interruption in females. Depression 
and other mental health issues are common in HIV–HCV 
  coinfection.28–30 In HCV populations, current levels of 
  psychiatric disorders range from 31% to 58% with lifetime 
rates as high as 95%.5 This may be higher in women compared 
to men.10 In HIV populations, psychiatric disorders are also 
common with up to 36% of individuals suffering from major 
depression, a rate that is three times higher than non-HIV 
infected individuals.31,32 Several studies suggest mental illness 
is more prevalent and more severe in the HIV–HCV coin-
fection.31–34 Studies evaluating HIV mono-infected patients 
suggest that much of the variation in HIV progression is 
related to depression, stressful life events, and trauma.32 In our 
analysis women were more likely to have a psychiatric illness 
and for this to affect their treatment. Mental health issues 
may also explain why women in our study had a decreased 
cumulative survival. Despite the well-established influence 
on mental health, the use of efavirenz did not appear to influ-
ence the likelihood of interrupting HAART in our cohort.35 
This data highlight the importance of thoroughly evaluating 
and treating mental health issues, especially in women, as 
such interventions may significantly improve outcomes in 
HIV–HCV coinfection.
Patients with HIV–HCV coinfection have higher 
  mortality rates.11 Little is known about gender differences 
among coinfected populations. Our results suggest that in 
the HIV–HCV coinfected population, mortality in women 
may be higher despite similar viral suppression and CD4 
counts, and when controlling for IDU history, race, and 
baseline CD4 levels. Recent data in HIV mono-infected 
individuals reveals that women generally live longer with 
HIV , which contradicts our findings and may indicate that the 
negative interaction between these two viruses is particularly 
  harmful in women.6 The primary cause for death was related 
to end-stage liver disease. HCV-related liver disease does 
progress more rapidly in women, which partially explains 
our results.36 This suggests that HIV–HCV coinfected women 
should be aggressively evaluated and treated for HCV . Mental 
health issues in women may have contributed to our findings. 
  Others have reported that HIV-positive women with chronic 
depressive symptoms are two times more likely to die and 
show greater declines in CD4 counts.10 We do not believe 
that the differential mortality rates observed in our analysis 
are a consequence of an era effect as the average date of 
initiation of HAART and the median duration of follow-up 
was similar by sex. We acknowledge that the high number 
of loss to follow-up in males may have skewed the data as 
the true outcomes of these patients, including the possibility 
of death, is unknown. Furthermore, it is difficult to separate 
biological differences from confounding socioeconomic and 
mental health factors which are well-established to influence 
adherence, morbidity, and survival.12,13
There are several limitations to the current study. Most 
patients were White. It is unclear whether race directly 
  influences the natural history of HIV–HCV coinfected 
  individuals.22 The patients evaluated in this study were 
OR = 4.46, 95% 
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Figure 2 Comparison of cumulative survival by sex.
Abbreviations: CI, confidence intervals; HAART, highly-active antiretroviral therapy; OR, odds ratio.Patient Preference and Adherence 2010:4 102
Emery et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  managed at a tertiary center offering specialized HIV 
care. Due to referral bias, a broader population of 
HIV–HCV coinfected individuals that are not referred or 
who have yet to seek care may have been missed. As a 
  retrospective evaluation, reporting bias and missing data 
may have influenced our findings. Nonetheless, our analysis 
  convincingly indicates that biological sex is not associated 
with differences in virological and immunological outcome 
in HIV–HCV coinfection initiating HAART. However, 
  reasons for treatment interruption and mortality itself may 
differ by sex. These findings are of value in guiding health 
care providers as they plan and manage gender-specific 
  treatment in HIV–HCV coinfection.
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